Capivasertib showed pre-clinical efficacy when used as a single agent for treating human breast cancer cell lines with alterations in PIK3CA and MTOR, and more so when combined with anti-HER2 and endocrine therapy [304]. Here, ERBB2 is linked to breast cancer.